My Screeners
No screeners
System Screeners
My Watchlists
No watchlists
System Watchlists
Loading...
Valerio Therapeutics is a biotechnology company based in Villejuif, France, that today focuses its core operations entirely on early‐stage drug discovery and preclinical research rather than clinical trials. Its principal business consists of developing proprietary technology platforms - V-Body and integrated chemistry - that enable creation of novel therapeutic candidates, particularly precision-guided modalities. It has discontinued all clinical stage operations, including its lead clinical trial (VIO-01), and closed its U.S. office to redirect resources toward discovery and partnership readiness.
The V-Body platform is centered on synthetic humanized single-domain antibodies (sdAbs, approximately 15 kilodaltons in size) intended to serve as biological vectors. These sdAbs are engineered for multiple therapeutic formats, including antibody-drug conjugates (ADCs), CAR-T sdAbs, V-Body - oligonucleotide conjugates, and T cell engagers, with target indications in rare diseases, autoimmune, inflammatory, and oncology fields. The integrated chemistry platform supports the development effort by providing linker/payload technologies, bioconjugation, stabilization, formulation, and hybrid molecule design, with the overall aim of generating preclinical proof‐of‐concept candidates ready for partnerships or licensing.
Valerio Therapeutics' business model now emphasizes technology/platform development and collaborative partnering rather than in-house clinical development. The company uses its V-Body and chemistry platforms to attract non-dilutive funding, exclusive licenses, and R&D collaborations. Markets it addresses include oncology; immune-mediated inflammatory disease; autoimmunity; rare and genetic diseases. R&D and discovery are centralized in France, especially through its subsidiary Valour Bio, which absorbed acquisition of Emglev Therapeutics and serves as the hub for V-Body platform activities, including library optimization and preclinical candidate selection.
Click to see warnings
Effective scoring profile: Standard company
Remaining score inputs are provider supplied.
Log in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see details
Log in for full accessLog in to see financial data
Log in for full accessIt is important that you understand how Findx arrives at Fair Value. Please take a minute to watch this short explainer.
It is very important that you understand this
Fair Value is an estimate, and you choose the basis it is built on. Do not invest based on our default without understanding how we calculate it.